Develop Health vs Humata Health
Two Prior Authorization vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| Develop Health | Humata Health | |
|---|---|---|
| Pricing model | Free to providers (funded by payers/pharma) · pharma-funded, free for prescribers | Enterprise contract (custom) · Priced on volume and workflow complexity |
| Speed to go live | API integration into existing EHR workflow | EHR-embedded, standard integration project |
| Automation model | Autonomous agents · automated benefit checks and PA submission | Autonomous agents · Touchless prior auth, exception-based review |
| Built for | Small practices, Mid-size groups, Enterprise systems | Mid-size groups, Enterprise systems, Payers |
| Security posture | HIPAA | SOC 2 Type II, HITRUST, HIPAA |
| Company maturity | 4 yrs (est. 2022) | 3 yrs (est. 2023) |
| Financial backing | $17.6M · Series A | $25M+ · Series A |
| Named customers | 4 named | 5 named |
| Published results | No public numbers | No public numbers |
| Documented integrations | 2 listed | 4 listed |
| Third-party validation | None found | None found |
Bottom line
- Pick Develop Health if medication prior auths bottleneck your prescribers and you want end-to-end PA automation at no cost to the practice.
- Pick Humata Health if prior auth volume is drowning your staff and you want touchless submissions inside the EHR with payer-grade compliance credentials.
Develop Health
AI benefit verification and prior auth for prescriptions
- Founded
- 2022
- HQ
- Menlo Park, CA
- Stage
- Series A
- Raised
- $17.6M
What it does
- Real-time benefit verification with plan-specific cost and coverage
- Predicts coverage and PA requirements at point of prescription
- Generates and submits prescription prior authorization packages
- Drafts appeals and manages denials automatically
- Returns structured coverage data into the prescriber's EHR
Where it's strong
- Purpose-built for prescription drug access (benefit checks plus medication PA), a narrower and deeper wedge than general prior auth vendors.
- Named traction with high-volume telehealth prescribers like Ro and LifeMD, where GLP-1 coverage friction makes the ROI easy to measure.
- Founders came from Canvas Medical and Rupa Health, so the product is built around real prescriber workflow integration rather than a standalone portal.
What buyers should weigh
- Total funding of $17.6 million and a 2022 founding date make this an early-stage vendor bet; assess team depth and support model before committing core volume.
- Public proof points are concentrated in telehealth and virtual care companies, so traditional health systems and pharmacies will find fewer reference customers.
- Scope is medications only; if you also need procedure, imaging, or DME prior auth, you will still need another vendor.
Named customers
Ro · LifeMD · Calibrate · Sunrise
Integrations
Humata Health
AI prior authorization for providers and payers
- Founded
- 2023
- HQ
- Orlando, FL
- Stage
- Series A
- Raised
- $25M+
What it does
- Matches payer policies to determine if prior auth is required
- Auto-gathers and bundles clinical documentation for submission
- Submits authorizations touchlessly across payer connections
- Monitors auth status and flags changes after submission
- Detects CPT mismatches before submission
- Supports gold-carding and exception-based review workflows
Where it's strong
- Founder Jeremy Friese, MD previously built and sold Verata Health, so this is a second product in the same category, not a first attempt.
- Strategic investors on the payer side (Blue Venture Fund, Optum Ventures, Highmark Ventures) give it unusual payer connectivity for a provider-facing tool.
- Real deployment scale for its age: roughly 225 hospitals and 42,000 physicians, plus CMS selecting it as a technology partner for the WISeR model.
What buyers should weigh
- Headline metrics like 96% first-pass approval and 45% fewer manual touches are vendor-reported, so validate them against your own service lines in a pilot.
- Its role as an AI clinical-review partner in the CMS WISeR model puts it on both the provider and payer sides of prior auth, which some provider organizations may see as a conflict.
- The company traces back to prior authorization assets from Olive AI, which shut down, so diligence which parts of the platform are new versus inherited.
Named customers
Texas Health Resources · Hartford HealthCare · Renown Health · Rochester Regional Health · Lee Health
Integrations
Compare against the rest of Prior Authorization
Deciding between these two?
First Pass tracks Prior Authorization every week: funding, launches, and what changed since this page was written.